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Abstract
Infection with hepatitis B virus (HBV) results in disparate degrees of tissue injury: it can replicate 
without pathological consequences or trigger immune-mediated necroinflammatory liver damage. 
We investigated the potential for myeloid-derived suppressor cells (MDSC) to suppress T cell-
mediated immunopathology in this setting. Granulocytic MDSC (gMDSC) expanded transiently in 
acute resolving HBV, decreasing before peak hepatic injury. In persistent infection, arginase-
expressing gMDSC (and circulating arginase) increased most in phases characterized by HBV 
replication without immunopathology, whilst L-arginine decreased. gMDSC expressed liver-
homing chemokine receptors and accumulated in the liver, their expansion being supported by 
hepatic stellate cells. We provide in vitro and ex vivo evidence that gMDSC potently inhibited T 
cells in a partially arginase-dependent manner. L-arginine-deprived T cells upregulated system-L 
amino acid transporters to increase uptake of essential nutrients and attempt metabolic 
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reprogramming. These data demonstrate the capacity of expanded arginase-expressing gMDSC to 
regulate liver immunopathology in HBV infection.
Immune responses in the liver are tightly regulated to preserve the integrity of this vital 
organ. Hepatotropic viruses such as HBV exploit the tolerogenic environment in the liver to 
establish persistent infection in around 350 million people worldwide. HBV is a non-
cytopathic virus; the liver disease it triggers, resulting in cirrhosis and hepatocellular 
carcinoma, is immune-mediated1. HBV can elicit starkly contrasting outcomes, recognized 
as distinct clinical phases; replicating at extremely high levels for decades without clinically 
apparent liver disease (“immunotolerant” phase), or, in contrast, driving a marked 
necroinflammatory reaction (active liver disease). The immune mechanisms distinguishing 
these phases, and the transition between them, have not been established.
In chronic HBV infection (CHB), an inadequate HBV-specific T cell response can trigger a 
large non-antigen-specific cellular infiltrate, amplifying liver damage through bystander T 
cells1-5. Here we have explored how such responses are blunted in phases when there is 
ongoing viral replication without overt liver inflammation, as a paradigm of 
immunoregulation of tissue damage. We previously noted a proliferative defect in global T 
cell responses in CHB accompanied by CD3-ζ-chain downregulation, a hallmark of L-
arginine deprivation6. We therefore postulated that nutrient deprivation might be a factor 
limiting T cell responses in the metabolically restricted environment of the liver. Recent data 
highlight the central role of the metabolic milieu in regulating immunity, with an increased 
requirement for amino acids imposed by the demands of mounting an effective immune 
response7,8.
A cell type increasingly recognized to exert potent immunoregulation through metabolic 
manipulation is the myeloid-derived suppressor cell (MDSC). These immature myeloid cells 
expand in tumor infiltrates, down-regulating local and systemic immune responses by, for 
example, production of arginase I, which catabolizes L-arginine to deprive immune effectors 
of this amino acid9. Emerging data also implicate MDSC in inhibiting antiviral 
immunity10-13 but their potential for regulating amino acid metabolism has not been 
examined in individuals with HBV infection.
In this study we demonstrate expansion of the granulocytic subset of MDSC (gMDSC) in 
subjects sustaining HBV replication without necroinflammatory liver disease. Our data 
indicate that this protective effect may be mediated by the capacity of gMDSC expressing 
arginase I to potently inhibit T cell responses. Our findings highlight the capacity of gMDSC 
to moderate tissue damage in a common human infection by constraining nutrient supplies 
to proliferating T cells.
Results
gMDSC expansion in subjects with HBV replication without liver damage
Circulating frequencies of gMDSC were quantified with the gating strategy indicated (Fig. 
1a), using freshly isolated samples since gMDSC are cryo-sensitive (Supplementary Fig. 
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1a)14. Flow cytometric identification of CD66b and CD16 and cytospin staining confirmed 
the granulocytic nature of the gMDSC population analyzed (Supplementary Fig. 1b-c)15,16.
The frequency of gMDSC was increased (mean 8-fold, maximum 20-fold) in a cohort of 84 
subjects with CHB (Supplementary Table I) compared to 44 healthy controls (as percentage 
of myeloid cells Fig. 1b, absolute numbers Supplementary Fig. 1d). This finding was 
reproducible in a separately sampled cohort (54 CHB, 55 healthy controls), although 
gMDSC frequencies were proportionately decreased in this cohort, attributable to collection 
of blood in EDTA versus heparin (Supplementary Fig. 1e).
In some patients with CHB, the expanded population of gMDSC accounted for as much as 
45% of circulating myeloid cells (Fig. 1b), whereas the monocytic subset of MDSC 
(mMDSC) was not significantly increased (Fig. 1c). The percent of gMDSC in CHB was 
highly variable (Fig. 1b, Supplementary Fig. 1e), with the spread not attributable to age or 
cytomegalovirus (CMV) serostatus (Supplementary Fig. 1f-g). However females with CHB 
(known to develop less HBV-related liver inflammation17) had higher frequencies of 
gMDSC than males (Fig. 1d). Examining virological parameters, gMDSC numbers did not 
correlate significantly with viral load, serum HBsAg titer or HBeAg status (Supplementary 
Fig. 1h-j); no interdependent relationship between these variables was detected using 
multiple linear regression or principal component analysis (data not shown).
HBV is a non-cytopathic virus, with disease activity attributed to the degree of 
immunopathology rather than viral replication. We therefore analyzed gMDSC frequencies 
in a subset of the cohort who could be classified by repeated assessment of clinical 
parameters into four major phases of disease activity: “immunotolerants”, “HBeAg+ active 
disease”, “inactive disease”, “HBeAg− active disease” (diagnostic cut-offs defined in Fig. 1e 
legend). Donors sustaining HBV replication in the absence of liver inflammation (assessed 
by repeated serum alanine transaminase (ALT) quantitation) had significantly higher 
gMDSC frequencies (Fig. 1e) and absolute numbers (data not shown) than those with active 
liver disease.
In 42 individuals, liver biopsy tissue was available for histological assessment of immune-
mediated pathology; the percentage of gMDSC correlated inversely with their hepatic 
necroinflammatory score (Fig. 1g). These findings were concisely displayed via hierarchical 
clustering by Euclidean distance (Fig. 1h). Clustering in an unsupervised manner based on 
similarity of ALT, necroinflammatory score and gMDSC frequencies showed that a high 
frequency of gMDSC was concordant with low ALT and necroinflammatory score. 
Immunotolerant and inactive disease clustered together, with HBeAg+ and HBeAg− active 
disease forming a separate cluster. Taken together, these data implicate a role for gMDSC in 
protecting against liver disease in CHB.
Temporal dynamics of gMDSC frequencies in acute and chronic HBV flares
To further dissect the relationship between HBV disease activity and gMDSC, we analyzed 
their frequency during the dynamic changes characterizing acute infection in three 
individuals who, unusually, had been sampled from the initial pre-clinical phase until 
disease resolution. We confirmed that although gMDSC are reduced by cryopreservation, 
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they remain in direct proportion to their ex vivo frequency (Supplementary Fig. 1a), allowing 
valid interpretation of longitudinal trends within these cryopreserved samples. In the two 
donors sampled before or at peak viremia, a clear temporal correlation between increases in 
gMDSC and HBV load was observed, with these parameters subsequently decreasing in 
parallel (Fig. 2a as percentage of myeloid, Supplementary Fig. 2a as percentage of live 
leukocytes).
Subjects showed the delay between peak viremia and subsequent hepatic flare (measured by 
ALT increases to >2000 IU/L) characteristic of acute HBV. Analogous to our cross-
sectional findings in chronic infection, gMDSC frequencies correlated inversely with ALT; 
highest when there was high-level viral replication without liver damage, and decreasing 
when the acute flare of hepatic injury peaked (Fig. 2b as percentage of myeloid, 
Supplementary Fig. 2b as percentage of live leukocytes). Samples obtained during the 
intermittent, spontaneous hepatic flares characteristic of HBeAg− chronic disease likewise 
showed a close inverse temporal relationship between liver inflammation and gMDSC 
frequencies (Fig. 2c as percentage of myeloid, Supplementary Fig. 2c as percentage of live 
leukocytes).
These findings are in line with data from the mouse lymphocytic choriomeningitis virus 
(LCMV) model, showing transient expansion of MDSC during acute infection, contrasting 
with their more sustained expansion during persistent infection10. Our results provide direct 
ex vivo evidence for the expansion of human gMDSC in acute HBV infection and their 
inverse temporal correlation with hepatic flares, further suggesting that they may suppress 
liver inflammation.
Degranulating arginase+ gMDSC in CHB without immunopathology
We next tested the postulate that gMDSC could suppress inflammation in CHB through the 
production of the enzyme arginase I. gMDSC, along with low density neutrophils, were the 
only circulating cell subsets showing strong staining for arginase I (Fig. 3a, Supplementary 
Fig. 3a), with consistently greater intensity than mMDSC (Supplementary Fig. 3b). Subjects 
with CHB had a high proportion of gMDSC expressing arginase I (mean ± SEM, 81.2 ± 
3.2%, data not shown). There was a marked increase in the proportion of arginase+ gMDSC 
circulating in CHB compared to controls (Fig. 3b), particularly in the immunotolerant and 
inactive phases of CHB (Fig. 3c).
Imagestream analysis showed a granular pattern of distribution of arginase I throughout 
gMDSC (Supplementary Fig. 3c). Surface expression of CD63 was increased on gMDSC in 
CHB compared to healthy controls (Supplementary Fig. 3d), indicative of an enhanced 
capacity to degranulate and release arginase I18,19. Serum arginase I was also increased in 
patients with CHB compared to controls (Fig. 3d), and correlated with gMDSC frequency 
(Fig. 3e), in line with this population being a major source of circulating arginase I. The 
preferential expansion of arginase+ gMDSC in the immunotolerant phase was mirrored by 
increased circulating arginase I concentrations in this group (Fig. 3f), and reflected in the 
inverse correlation between serum arginase I and ALT (Fig. 3g, Supplementary Fig. 3e).
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Ex vivo evidence of selective L-arginine depletion in CHB
To corroborate the functionality of arginase+ gMDSC, we used tandem high-performance 
liquid chromatography mass spectrometry to quantitate L-arginine, the amino acid substrate 
of arginase I. Consistent with their expanded population of arginase+ gMDSC, individuals 
with CHB, particularly those without liver inflammation, had lower serum concentrations of 
L-arginine than healthy controls (Fig. 3h, Supplementary Fig. 3f). L-tryptophan, also 
implicated in immune regulation20, showed a non-significant trend to decrease in CHB 
(Supplementary Fig. 3g), whereas L-phenylalanine did not differ (Supplementary Fig. 3h).
To further probe the contribution of HBV infection to the gMDSC-dependent depletion of 
L-arginine, we obtained samples from 7 individuals before and during antiviral therapy. We 
observed that L-arginine levels were partially restored in 5 out of 7 patients once HBV 
replication was suppressed by antivirals (Fig. 3i), the degree of L-arginine increase robustly 
correlating with the extent of disease suppression (Fig. 3j).
Accumulation of arginase+ gMDSC in the liver
We next investigated whether the expanded population of gMDSC circulating in subjects 
with CHB could home to the liver to regulate inflammation at the site of HBV replication. 
Simultaneous quantitation of gMDSC from paired blood and surplus liver biopsy tissue from 
36 subjects with CHB showed that gMDSC accumulated in the liver (maximum 56% of 
intrahepatic myeloid cells Fig. 4a, and 9% of total live liver cellular extracts Supplementary 
Fig. 4a). By contrast, mMDSC were reduced in the intrahepatic compartment 
(Supplementary Fig. 4b). Samples from a cohort of individuals with chronic HCV infection 
revealed that another hepatotropic viral infection could also drive the expansion of gMDSC 
in the blood and enrichment in the liver compartment (Supplementary Fig.4c-d).
In individuals with CHB, intrahepatic gMDSC expressed more arginase I and surface CD63 
than their circulating counterparts (Fig. 4b-c), consistent with an enhanced potential to 
release arginase I and mediate immunosuppression by L-arginine depletion within the liver. 
Arginase I levels were markedly increased in gMDSC compared to other cellular fractions in 
liver extracts (Supplementary Fig. 4e). An additional potential source of arginase I is 
necrotic hepatocytes, but this has low extracellular stability due to rapid loss of divalent 
metal ions and requires an alkaline pH for full activity21-23 (Supplementary Fig. 4f). In 
contrast, arginase+ gMDSC co-express azurophilic granules (identified by their expression 
of myeloperoxidase (MPO), Supplementary Fig. 4g), that can release a factor critical for 
activating arginase I at physiological pH24.
We then stained circulating gMDSC for chemokine receptors potentially relevant to their 
mobilization or liver-homing, based on recent studies25. CCR2, critical for the mobilization 
of MDSC from the bone marrow in LCMV10, was expressed at high levels on mMDSC but 
barely detectable on gMDSC (Fig. 4d). Loss of signaling through another chemokine 
receptor, CXCR4, promotes the egress of immature granulocytes from the bone 
marrow26,27; CXCR4 was expressed at reduced levels on gMDSC in CHB (Fig. 4d), 
suggesting its downregulation may have accelerated their mobilization. Expression of 
CXCR3 was markedly increased on gMDSC in the liver compared to the circulation (Fig. 
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4e, Supplementary Fig. 4h), whilst CXCR1 was expressed at high levels by circulating and 
intrahepatic gMDSC (Fig. 4f, Supplementary Fig. 4i), potentially allowing them to interact 
with hepatic stellate cells, that can produce the chemotactic cytokine IL-828.
Hepatic stellate cells are specialized, liver-resident stromal cells, recently reported to be able 
to support the expansion of MDSC29-31. We isolated and cultured primary hepatic stellate 
cells (pHSC) from healthy resected liver tissue and found they increased the expansion of 
gMDSC in PBMC from controls or subjects with CHB (Fig. 4g). Taken together, these data 
suggest that downregulation of CXCR4 may favor the egress of gMDSC from the bone 
marrow into the circulation in CHB, whilst their accumulation in the liver could be directed 
by their expression of CXCR3 and CXCR1, and supported by pHSC. Their potential to 
interact with pHSC was underscored by visualizing gMDSC within the liver sinusoids in 
sections from HBV-infected livers, where they were also forced into close proximity with 
infiltrating T cells (Fig. 4h-i).
gMDSC suppress HBV-specific and bystander T cell responses
To investigate whether gMDSC had the potential to suppress the T cells they encounter in 
the liver, we tested their impact on the expansion of HBV-specific T cells in co-culture. 
HBV-specific T cell IFN-γ responses were rescued by depletion of gMDSC (Fig. 5a and 
Supplementary Fig. 5a). Conversely, HBV-specific CD4+ and CD8+ T cell responses were 
almost completely abrogated by the addition of gMDSC (Fig. 5a-b).
We next sought functional evidence that L-arginine deprivation by gMDSC could suppress 
bystander T cell responses, that play a crucial role in amplifying HBV-related 
immunopathology in mouse models and human disease1,3. To investigate this we analyzed 
subjects with CHB for pooled influenza, Epstein-Barr virus (EBV) and CMV-specific T cell 
responses. Again, removal of gMDSC increased expansion of peptide-specific IFN-γ+ T 
cells, whereas their re-addition suppressed responses to these viruses in all donors (Fig. 5c-
d), even at an effector:target ratio of 1 to 4 (Supplementary Fig. 5b).
Treatment of gMDSC with the specific arginase I inhibitor N-hydroxy-nor-L-arginine (nor-
NOHA) reduced their suppressive activity, partially restoring T cell IFN-γ responses (Fig. 
5e). Addition of nor-NOHA to PBMC produced marginal increases in responses, congruent 
with the lower frequency of arginase+ gMDSC (Fig. 5e). gMDSC could likewise suppress 
other CD8+ T cell functions potentially contributing to liver damage (TNF-α and granzyme 
B) in an arginase-dependent manner (Supplementary Fig. 5c-d). T cells cultured with 
gMDSC showed downregulation of CD3-ζ and impaired proliferative capacity, hallmarks of 
L-arginine deprivation6,32 (Supplementary Fig. 5e). gMDSC obtained by flow cytometry 
instead of bead-sorting (purity Supplementary Fig. 5f) similarly suppressed T cell cytokines 
and down-regulated CD3-ζ (Supplementary Fig. 5g).
To investigate the effect of gMDSC on T cells directly ex vivo, we examined the temporal 
changes in CD3-ζ (as a hallmark of L-arginine deprivation) in parallel with fluctuations in 
gMDSC frequencies over the course of acute and chronic flares of HBV disease. In all 
flaring patients in whom gMDSC had been quantitated longitudinally (Fig. 2), we observed 
a striking ex vivo inverse temporal relationship between numbers of gMDSC and CD3-ζ 
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expression on global T cells (Fig. 5f). These findings suggested that gMDSC could impede 
T cell responses capable of driving liver pathology by depleting their L-arginine supply.
L-arginine deprivation induces system-L amino acid transporters
Uptake of certain essential amino acids by T cells is dependent on the system-L amino acid 
transporters, that have recently been shown to play a critical role in the metabolic 
reprogramming required for a proliferative response to TCR-mediated signaling7,33. We 
therefore stained for CD98 on T cells to identify the family of system-L amino acid 
transporters (Slc7a5, Slc7a6, Slc7a7, Slc7a8) that form heterodimers with the CD98 heavy 
chain7,34. Ex vivo levels of CD98 on T cells were low, but were increased in some 
individuals with CHB compared to healthy controls (Fig. 6a, Supplementary Fig. 6a).
It has previously been shown that levels of Slc7a5 on rat hepatocytes can increase in 
response to L-arginine starvation35. We hypothesized that T cells infiltrating the extensive 
liver vasculature could be subjected to prolonged periods of L-arginine deprivation, 
manifested as a compensatory increase in Slc7a5 (and monitored by CD98 expression). To 
investigate this, paired blood samples and liver biopsy tissue from 11 individuals with CHB 
were used for the comparison of circulating and intrahepatic T cells. The number of T cells 
expressing CD98 directly ex vivo, and the level of their expression, was increased in the 
intrahepatic compared to circulating compartment in all patients examined (Fig. 6b, 
Supplementary Fig. 6b). We therefore investigated the expression of CD98 on HBV-specific 
CD8+ T cells, which would have encountered their antigen in the liver milieu, identified 
directly ex vivo by HLA-A2/HBV-peptide multimer staining. HBV-specific CD8+ T cells 
had significantly higher expression of CD98 than global CD8+ T cells in all subjects 
examined (Fig.6c, Supplementary Fig. 6c). HBV-specific CD8+ T cells also had consistently 
higher CD98 than their CMV-specific CD8 T cell counterparts in the same individuals (Fig. 
6d, Supplementary Fig. 6d), which in turn had higher expression than the global population 
of CD8+ cells in these subjects with CHB (Supplementary Fig. 6e).
To test whether the increases in CD98 we observed in intrahepatic and virus-specific T cells 
in CHB could represent a compensatory response to L-arginine deprivation, we starved 
TCR-stimulated T cells of L-arginine in vitro. We noted a progressive upregulation of CD98 
on T cells in response to decreasing concentrations of L-arginine in the medium (Fig. 6e). 
Following L-arginine deprivation, T cells with the highest upregulation of CD98 showed 
increased expression of the transferrin receptor CD71 (Fig. 6f), suggestive of an alteration in 
cellular metabolism7. The compensatory increases in CD98 expression driven by L-arginine 
starvation were accompanied by substantial increases in the capacity of TCR-stimulated T 
cells to take up radioactively labeled phenylalanine (Fig. 6g). This was due to the specific 
capacity of L-arginine deprivation to increase the function of the system-L transporters 
utilized by essential, large, neutral amino acids such as phenylalanine and leucine, since the 
effect was abrogated using a small molecule inhibitor of these transporters (2-amino-2-
norbornanecarboxylic acid, BCH) (Fig. 6h). Thus L-arginine starvation imposed on T cells 
by arginase+ gMDSC has the potential to drive reprogramming of their metabolic response 
to TCR engagement.
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Discussion
CHB is a highly prevalent disease in which the differential regulation of immune-mediated 
tissue damage results in markedly contrasting outcomes of infection. Using blood and liver 
samples from well-characterized cohorts with diverse clinical phases of acute and chronic 
disease, we demonstrate MDSC-mediated arginase-dependent regulation of 
immunopathology. A subset of MDSC with some characteristics of immature granulocytes 
(gMDSC) is expanded in the circulation and liver, particularly in those individuals in whom 
HBV replicates at high levels without triggering overt immunopathology. gMDSC potently 
suppress the proliferative expansion of HBV-specific and bystander T cell responses, 
previously implicated in the liver damage triggered by HBV infection. The correlations 
between circulating gMDSC, arginase I, T cell ζ-chain and the degree of liver pathology, 
point to the relevance of metabolic immunoregulation in vivo. This is further reinforced by 
our data showing differential expression of key amino acid transporters on virus-specific and 
organ-infiltrating T cells that can be driven by L-arginine starvation and modulates uptake of 
other essential nutrients.
Human MDSC have been shown to release arginase I upon degranulation16, consistent with 
the correlation we observed between gMDSC frequencies and serum arginase I 
concentrations. Necrotic hepatocytes are another source of arginase I36,37; we previously 
postulated that arginase I transiently induced in acute38 and chronic6 flares of HBV infection 
might derive from damaged hepatocytes. We now show that increases in arginase I occur in 
the “immunotolerant” and “inactive” phases of CHB, that likely predominantly derive from 
the concurrent increase in arginase+ gMDSC, since there is minimal hepatocyte damage in 
these settings. The depletion of L-arginine and accompanying global T cell changes noted in 
the circulation6,38,39 are unlikely to be sufficient to markedly impair peripheral immune 
responses, in line with the lack of obvious generalized immunosuppression. However in the 
local liver milieu, gMDSC accumulate, express and degranulate more arginase I, and can be 
visualized in close association with T cells in the narrow-lumen sinusoidal vasculature; this 
would maximize the effects of local nutrient depletion and any contact-dependent 
interactions. Activation of locally infiltrating MDSC to express more arginase I, allowing 
enhanced suppression of neighboring bystander T cell responses, has similarly been reported 
in a mouse tumor model40.
Depriving T cells of adequate supplies of L-arginine in vitro inhibits their proliferation by 
arresting them in G0/G141, reflected in CD3-ζ downregulation and defects in the expansion 
of functional responses in CHB6. The capacity of gMDSC to deprive T cells of L-arginine is 
underscored by our new observation of a close inverse temporal correlation between 
gMDSC frequencies and T cell CD3-ζ chain levels ex vivo. We show that virus-specific T 
cells can also differentially regulate their expression of key amino acid transporters in vivo, 
providing an additional rheostat to modulate the intracellular availability of amino acids in 
persistent viral infections. This is supported by recent work demonstrating that the system-L 
transporter, Slc7a5, functions as a critical checkpoint to control the metabolic response of T 
cells to antigen7. We find that compensatory upregulation of system-L transporters in 
response to extracellular deprivation of L-arginine can enhance T cell uptake of essential 
amino acids like phenylalanine and leucine that, like L-arginine, regulate effector function 
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through mTOR7,42. This exemplifies a novel paradigm, whereby metabolically stressed T 
cells can attempt to reprogramme by selectively increasing their nutrient supply.
Although our data implicate arginase I as a major effector mechanism of the gMDSC 
population expanded in CHB, it is likely they can utilize supplementary suppressive 
mechanisms9. In addition to suppressing HBV-specific and bystander T cells that mediate 
cytolysis and produce pro-inflammatory cytokines, it remains to be determined whether 
MDSC can exert other anti-inflammatory effects in the HBV-infected liver. Future work 
should address whether gMDSC can induce Tregs to amplify their immunosuppressive 
effects9, inhibit the capacity of Kupffer cells to limit immunopathology43 or downregulate 
hepatic NK cells or macrophages contributing to bystander liver damage in HBV4,5,44. In 
support of this concept, work in other models has revealed inhibition of macrophage pro-
inflammatory cytokines by MDSC45 or L-arginine deprivation46.
What factors drive and maintain the expansion of suppressive gMDSC in viral hepatitis? 
Our data from early acute HBV infection support a contribution for the virus in triggering 
their induction. Their increase in hepatotropic infections, and enrichment and enhanced 
function in the intrahepatic compartment, led us to question the role of the liver milieu in 
sustaining them. Hepatic stellate cells can promote immunosuppression by augmenting 
expansion of MDSC in vitro29-31, as we observed, and in vivo29. The pathways involved, 
and whether they induce MDSC proliferation and/or enhance their survival, remain to be 
elucidated. In addition to the chemokine receptors we described, a number of other 
candidate drivers including TNF-α, IL-6, vascular endothelial growth factor, hypoxia-
induced HIF-1-α9,40,47 and γδT cells48, merit investigation for their potential contribution to 
the differential accumulation of gMDSC in the distinct phases of CHB.
Our results point to a role for gMDSC in sustaining the state of immunotolerance to high 
levels of HBV replication characterizing the first decades of infection. The increase in 
gMDSC in female patients is in line with their 3–fold decreased risk of liver inflammation 
during CHB compared to men17. Patients in the immunotolerant phase of CHB, who 
constitute a huge infectious reservoir, have generally not been considered for antiviral 
therapy because of their reduced response rate and the view that their disease is 
immunologically inactive. However recent findings challenge this, highlighting that T cells 
may be less exhausted at this earlier phase of infection49. Our results suggest that the 
immunotolerant phase is characterized by active downregulation of inflammatory immune 
responses rather than immune ignorance, raising the possibility of targeting MDSC or amino 
acid metabolism to manipulate T cell responses. An important first step will be to investigate 
whether the expanded population of arginase+ gMDSC can be corrected if subjects in the 
immunotolerant phase are treated with existing antivirals. More broadly, our findings point 
to the need to investigate the role of MDSC in other types of liver disease, and serve to 
underscore the importance of metabolic regulation of immunopathology in the setting of 
chronic antigenic stimulation.
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Online methods
Patients and healthy controls
This study was approved by the local ethical boards of Camden Primary Care, The Royal 
London Hospital, University College Hospital or The Royal Free Hospital, with all 
participants giving written informed consent. Donors with CHB were anti-HCV and anti-
HIV antibody negative and treatment naïve, unless otherwise stated. CMV serostatus was 
determined by measurement of IgG using a commercial assay system (Abbot Architect). All 
donors with chronic HBV or HCV were stratified by serum levels of HBsAg (IU/ml) and 
HBeAg status (where appropriate), viral load (IU/ml, determined by real-time PCR) and 
degree of liver inflammation by serum alanine transaminase (ALT IU/L). Sample size was 
based on the standard deviation of gMDSC frequencies and the need for sufficient donors to 
analyse distinct disease phases. Donors with CHB were assigned to disease phases by their 
clinicians, who integrated virological, biochemical and histological data from several clinic 
visits. A cohort of 7 patients with active CHB (viral load 15,000-14million, ALT 59-1208 
IU/L) were sampled on a second occasion after at least 1 year of effective antiviral therapy. 
Intrahepatic lymphocytes were obtained from liver biopsy material surplus to diagnostic 
requirements; liver necroinflammation was scored as part of their routine histological 
assessment using the Knodell score for Histological Activity Index. Characteristics of all 
patients and controls are summarised in Supplementary Table I.
PBMC and intrahepatic lymphocyte isolation
PBMC were isolated by gradient centrifugation on Ficoll-Hypaque Plus (GE Healthcare) 
and used immediately as described below. Sera were collected and frozen for later use. 
Intrahepatic lymphocytes were isolated as previously described 6.
Assessment of absolute number of gMDSC
Absolute counts for gMDSC were assessed using BD TruCount tubes from heparinised 
whole blood on a small cohort of healthy controls and subjects with CHB according to the 
manufacturer’s instructions (BD Bioscience).
Flow cytometric analysis
Multi-parametric flow cytometry was used for phenotypic and functional analysis of PBMC. 
For gMDSC phenotyping, combinations of the following monoclonal antibodies (mAb) 
were used: CD11b-PECy7, HLA-DR-eFluor450, CD33-AlexaFluor700, CD16-APC-
eFluor780, CD63-PE, CD15-APC, CD14-HorizonV500, CD66b-PerCPCy5.5, CXCR1-
FITC, CCR2-PE, CXCR3-PerCPCy5.5, CXCR4-PE, MPO-PE and arginase I-FITC. For T 
cell analysis, combinations of the following mAb were used: CD3ε-PECy7, CD8-
AlexaFluor700, CD4-APC-eFluor780, CD3-ζ-PE, granzyme B-FITC, HLA-DR-
HorizonV500, CD14-HorizonV500, CD19-BD-HorizonV500, IFN-γ-HorizonV450, Ki67-
PE, TNF-α-APC, CD98-FITC and CD71-APCCy7. Full details can be found in 
Supplementary Table 2. Briefly, cells were stained with a fixable Live/Dead dye (Life 
Technologies) before being stained for surface mAb; 30 minutes at 4 °C with saturating 
concentrations of mAb in the presence of FcR blocking reagent (Miltenyi Biotec). Cells 
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were fixed and permeablized with Cytofix/Cytoperm (BD Bioscience) and intracellular 
proteins detected with saturating mAb; 30 minutes at 4 °C. All samples were acquired on a 
LSRII (BD Biosciences) and analyzed using FlowJo (Tree Star).
Dextramer staining of virus-specific T cells
HBV- and CMV-specific HLA-A2 dextramers (Immudex) were used for detection of virus-
specific cells. For detection of HBV-specific CD8+ T cells the following pool of HLA-A2/
peptide dextramers was used: core 18-27 (FLPSDFFPSV), envelope 183-91 (FLLTRILTI), 
envelope 335-42 (WLSLLVPFV), envelope 348-57 (GLSPTVWLSV), polymerase 455-463 
(GLSRYVARL), polymerase 502-10 (KLHLYSHPI) and for CMV-specific T cell detection 
a dextramer against the HLA-A2-restricted CMV epitope: NLVPMVATV was used. As a 
control for non-specific dextramer binding, a dextramer loaded with an irrelevant peptide 
was used in parallel. Briefly, cells were stained with dextramers; 37 °C in PBS, washed 
twice in cRPMI and left to rest for 1hr before further mAb staining as above. During 
analysis, stringent gating criteria were applied with doublet, dead cell and CD19+, CD14+ 
exclusion to minimize non-specific binding contamination.
Detection of serum arginase-1
Arginase I was detected in sera from healthy controls and subjects with CHB by ELISA, 
according to the manufacturer’s instructions (Hycult).
Tandem HPLC-MS for amino acid quantification
Circulating L-arginine, L-tryptophan and L-phenylalanine levels were determined from sera 
using tandem high-performance liquid chromatography with mass spectrometry detection 
(tandem HPLC-MS), with the stable isotope dilution method. Briefly, a known 
concentration of a stable isotope-labeled amino acid (Cambridge Isotopes) was added to sera 
for later determination of recovery. Sera were then de-proteinised by the addition of cold 
trichloroacetic acid (TCA, Fisher) and samples centrifuged (13,000 rpm, 10 minutes, 4 °C) 
to remove bulk protein. The supernatant was separated using a Dionex Ultimate 3000 HPLC 
system (Dionex) fitted with a Pinnacle DB biphenyl column (1.9 μm, 50×21 mm; Thames 
Restek) at a flow rate of 0.4 ml/min using a gradient mobile phase of water:acetonitrile with 
0.1% formic acid (10% acetonitrile rising to 90% over 6 minutes) and measured using a 
Orbitrap XL (Thermo Fisher) mass spectrometer in positive ion mode. Sample 
concentrations were determined by comparison to standard curves and corrected for 
recovery using the added stable isotopes.
gMDSC Suppression Assays
gMDSC were enriched or depleted using sequential magentic bead isolation: CD14 and 
CD15 positive selection kits (CD14−CD15+) (Miltenyi Biotec) as per the manufacturer’s 
instructions. In selected cases gMDSC were highly purified by flow cytometry on the basis 
of CD11b, CD14 and CD15 expression on a FACSAria (BD Bioscience). Where indicated 
PBMC or PBMC enriched/depleted of gMDSC were stimulated with either: 0.5 μg/ml of an 
HLA-A and HLA-B-restricted peptide pool spanning the immune-dominant proteins of 
CMV, EBV and influenza (CEF) (JPT Peptide Technologies), 1 μg/ml overlapping peptides 
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(pool of 15-mer peptides overlapping by 10 residues) spanning the core of HBV genotype D 
(JPT Peptide Technologies), 1 μg/ml HLA-A2-restricted NLVPMVATV peptide from CMV 
pp65 (ProImmune) or 0.5 μg/ml plate-bound anti-CD3 and 0.5 μg/ml anti-CD28 
(eBioscience). All cultures were carried out in the presence of 20 IU/ml recombinant human 
IL-2 (Miltenyi Biotec) in cRPMI (Life Technologies) for 5-7 days at 37 °C. Specific 
responses were detected by intracellular cytokine staining after re-stimulation on day 4/6 in 
the presence of 1 μg/ml brefeldin-A (BFA, Sigma-Aldrich). Where indicated, 0.5 mM N-
hydroxyl-nor-L-arginine (nor-NOHA) (Calbiochem), an arginase I specific inhibitor, was 
added to the culture on day 0.
Specific enzymatic activity of arginase I
Human liver tissue was homogenised (TissueLyser II, Qiagen) in ice-cold Tris-HCL buffer 
(10mM, pH 7.2; with 158 mM NaCl, 1 mM EDTA and 1% Triton ×100) at a ratio of 1:4 
tissue to buffer. Isolates were then centrifuged (13,000 rpm at 4 °C for 10 minutes) to 
remove the remaining solid material. For the determination of arginase I activity, 
supernatant from the tissue preparation was incubated at increasing pH to determine the rate 
of conversion of L-arginine to urea. To start the reaction, tissue supernatant (100 μl) was 
added to a solution containing MnCl2 (0.7 mM), Saponin (0.3%) and L-arginine (18 mM) in 
glycine-NaOH buffer (50 mM) at pH values of 7.5, 8, 8.5, 9 and 9.5. The solutions were 
incubated at 37 °C, with aliquots removed at time 0, 20 and 40 minutes. The reaction 
stopped by the addition of tungstic acid solution (2.5% w/v, in 1 M HCL, 1 M H2SO4) at a 
ratio of 3:1 reaction mix:stop solution. Urea concentrations were determined in the resulting 
supernatant using a COBAS Integra II clinical analyzer (Roche) according to manufacturers 
instructions. Enzyme activity was calculated in IU as μmoles urea produced per minute per 
gram of wet weight tissue.
Imagestream Analysis
ImageStream technology was used to analyze the intracellular distribution of arginase I. 
PBMC were isolated and stained using the following mAb: CD11b-PEcy7, CD15-
AlexaFluor700, CD16-PE, HLA-DR-V500, arginase I-FITC. After staining, cells were fixed 
using Cytofix/Cytoperm (BD Bioscience) as per the manufacturer’s protocol. The sample 
was processed on an Amnis ImageStreamX Imaging Flow Cytometer (MERK-Millipore) 
fitted with a 60× microscope objective. Raw image files were acquired using INSPIRE 
software. After acquisition, a compensation matrix was applied to the data to correct for 
spectral overlap. Data analysis was done using IDEAS software, displaying PBMC using 
gradient RMS for the brightfield channel to exclude out of focus cells and a combined Area 
to Aspect Ratio dot plot ensured gating on single-cell events. Cells were then gated as: 
CD11b+CD15+CD16+ for gMDSC identification, excluding cells expressing HLA-DR.
Primary hepatic stellate cell isolation
Primary hepatic stellate cells (pHSC) were isolated from normal liver margins in patients 
undergoing hepatic resection for metastatic cancer. All patients signed informed consent, 
approved by the Royal Free Hospital ethics committee. For extraction of pHSC, fresh post-
resection liver tissue was washed thoroughly, passed through a tissue press and digested 
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with DNAseI (0.001%, Roche) and collagenase IV (0.01%, Life Technologies). Cellular 
homogenate was filtered through a 70 μm cell strainer and centrifuged at low speed to 
remove remaining parenchymal cells, then at 450 g to wash the cells. The remaining cells 
were layered for density gradient isolation using Optiprep (Sigma-Aldrich). After isolation, 
pHSC were suspended in Stellate Cell Medium® (ScienCell Research Laboratories), plated 
at a density of 5×104 cells/cm in tissue culture flasks and cultured at 37 °C in a humidified 
atmosphere with 5% CO2. On day 2-4, cell debris and non-adherent cells were removed by 
washing. When cultures reached confluence, cells were trypsinized and replated; cells were 
passaged twice before freezing.
Primary hepatic stellate co-culture
Pre-isolated pHSC were thawed and cultured in 25 cm2 tissue culture flasks in Stellate Cell 
Medium® to approximately 90% confluence. Cells were detached with trypsin–EDTA (Life 
Technologies), re-plated in 24 well plates in cRPMI with 10% FBS at 50,000 cells/well and 
left for 24–48 hrs to adhere. Once plated pHSC were incubated with 2×106 freshly isolated 
PBMC in cRPMI for 6 days prior to staining for gMDSC frequencies as above.
CD98 upregulation upon amino acid starvation
To assess the upregulation of amino acid transporters on the surface of T cells, whole PBMC 
were stimulated with 0.5 μg/ml plate bound anti-CD3 for 3 days in cRPMI in flat bottom 96 
well plates. On day 3 PBMC were transferred to U bottom 96 well plates, washed once in 
PBS, and replaced for 24 hrs with: RPMI, L-arginine free media, or RPMI supplemented 
with 50 μM L-arginine, all without FBS. After culture PBMC were stained for live/dead, 
CD3, CD98 and CD71 as above.
Amino acid uptake
Between 0.5 and 1×106 cells were resuspended in 0.4 ml Hank’s balanced-salt solution (Life 
Technologies) containing 3HL-phenylalanine (0.5 μCi/ml) (Perkin Elmer) with a final 
extracellular L-leucine concentration of 5 μM. Where indicated, 10 mM BCH (2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, Sigma) was added to the uptake medium. 
Amino acid uptake was assayed for 4 minutes with samples layered over 0.5 ml of a mixture 
of silicone oil (Dow Corning 550 (BDH silicone products); specific density, 1.07 g/ml) and 
dibutyl phthalate (Fluka) at a ratio of 1:1. Cells were pelleted below the oil, the uptake 
media above the oil layer aspirated. Following 3 washes, the silicon oil–dibutyl phthalate 
mixture was aspirated, and the cell pellet underneath was resuspended in 200 μl NaOH (500 
mM). β-radioactivity was measured by liquid scintillation counting in a Beckman LS 6500 
Multi-Purpose Scintillation Counter (Beckman Coulter). Each data point was performed in 
triplicate.
Immunohistochemistry
Core needle biopsy specimens were obtained from patients with CHB for diagnostic 
purposes and were formalin-fixed and paraffin-embedded. Immunohistochemistry was 
carried out using a Leica BondMax immunostainer (Leica Biosystems, UK). Slides were de-
waxed, rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate 
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buffer, pH 6, or EDTA-TRIS buffer, pH 9, for 10 minutes, and allowed to cool, followed by 
15 minutes incubation at room temperature with the primary antibody (CD15 (Rabbit) – 
Novus Biologicals NBP2-21754 1:50 pH 6, CD66b (Mouse) – BD Biosciences 555723 1:50 
pH 9, CD3 (Rabbit) – Dako A0452 1:100 pH 9). The signal was detected using the Leica 
Polymer Refine Detection System, Rabbit/Mouse (DAB) and Leica Polymer Define Red 
Detection System, Rabbit/Mouse (Fast Red), catalogue numbers DS9800 and DS9390. The 
slides were then dehydrated with alcohol, cleared with xylene and cover slipped with DPX 
(Leica Biosystems, UK) after hematoxylin counterstaining. Images were captured and 
processed with a Nikon Eclipse E600 microscope using the Nuance™ 3.0.2 (PerkinElmer, 
UK) multispectral imaging technology. Distinguishing between brown and red and 
unmixing these co-localized chromogens was not feasible by eye or with an RGB camera so 
a multispectral approach was used. Nuance camera takes several images over different 
wavelengths, thus identifying the ‘individual spectral signature’ of each chromogen, saving 
and unmixing it from adjacent colours. Once unmixed, the images were re-coloured, 
enabling distinction of chromogens and inverting to a pseudo-fluorescence image.
Statistical analysis
Natural variance in the data is demonstrated, as all data are displayed for cohort analysis. 
Statistical analyses were performed in Prism (GraphPad) using appropriate tests as indicated 
in legends (unpaired t test, paired t test, one way ANOVA (Tukeys multiple comparisons 
test), or Pearson product-moment correlation coefficient), with significant differences 
marked on all figures. All test were carried out as two-tail tests and for all tests, significance 
levels were defined as: * = p<0.05, ** = p<0.005, *** = p<0.001. Multivariate analyses 
were conducted in R 3.0.2, an open-source programming language for statistical computing. 
Hierarchical clustering was performed using Euclidean distance as the metric to calculate 
the similarity of each subject to one another.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. gMDSC expand in subjects replicating HBV in the absence of immunopathology
a) Sequential gating strategy for gMDSC identification (CD11bhighCD33+HLA-
DR−CD14−CD15+) using 11-color flow cytometry from freshly isolated PBMC (doublet 
discrimination not shown). gMDSC population (superimposed in red) was calculated as a 
percentage of myeloid cells (CD11bhighCD33+). Cumulative dot plots showing circulating 
b) gMDSC and c) mMDSC frequencies (n=44, healthy controls; n=84, CHB). d) gMDSC 
frequencies analyzed by gender. e) Summary plot of frequencies classified by disease phase 
using a subset of the cohort with clearly defined disease phases: 14 “immunotolerants” 
(HBeAg+, HBV DNA >107 IU/ml, ALT <40 IU/L), 9 “eAg+ active disease” (HBV DNA 
>5×105 IU/ml, ALT >60 IU/L), 21 “inactive disease” (HBeAg−, HBV DNA <2000 IU/ml, 
ALT <40 IU/L), 11 “eAg− active disease” (HBeAg−, HBV DNA >5×105 IU/ml, ALT >60 
IU/L). f) gMDSC frequencies according to hepatic necroinflammatory score (n=42, CHB). 
g) Unsupervised hierarchical clustering using Euclidean distance; dendrogram displaying 
similarity between clusters. Clinically assigned disease phase, shown adjacent to plot; 
immunotolerant: dark green, eAg+ active disease: dark yellow, inactive disease: pale green, 
eAg− active disease: pale yellow (not used for analysis). Increasing color intensity (blue–
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red) corresponds to increasing gMDSC frequency, ALT (IU/L) or necroinflammatory score 
(n=42, CHB; maximum Knodell score in this cohort = 9/18). Error bars represent the mean 
± SEM for the cohorts indicated; * p<0.05, ** p<0.01; *** p<0.001; b-c unpaired t test; d-e 
one way ANOVA (Tukey’s multiple comparisons test); f Pearson product-moment 
correlation coefficient.
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Figure 2. gMDSC are transiently induced in acute HBV infection and decline before acute and 
chronic hepatic flares
gMDSC were quantitated as a percentage of total myeloid cells (CD11bhighCD33+) from 
PBMC cryopreserved from multiple time points from the onset of viraemia and subsequent 
hepatic flare. a) gMDSC frequencies in relation to viral load in three subjects with acute 
HBV infection sampled from the pre-clinical phase through to HBV disease resolution. b) 
gMDSC frequencies plotted with the temporal course of liver inflammation (serum ALT, 
IU/L) in the same three patients with acute HBV and c) in two subjects experiencing 
spontaneous flares of chronic HBeAg− disease (days or months from initial presentation in 
clinic).
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Figure 3. Arginase+ gMDSC and circulating arginase I increase in patients with HBV replication 
without immunopathology, whilst L-arginine levels decline
a) Analysis of PBMC subpopulations for expression (MFI) of intracellular arginase I. 
Cellular fractions identified as: CD3−CD19+ B cells, CD14− CD16+CD15+ low density 
neutrophils, CD3+ T cells, CD3−CD56+ NK cells, HLA-DR+CD14+ monocytes, 
CD11bhighCD33+HLA-DRlowCD14+CD15− mMDSC. b) Cumulative data for percentage of 
arginase-I-expressing gMDSC as a proportion of total myeloid cells (CD11bhighCD33+; 
n=25, healthy controls; n=31, CHB). c) Arginase+ gMDSC as a percentage of total myeloid 
cells categorised by disease phase (defined in the legend to Figure 1). d) Serum arginase I 
(ng/ml) concentration, determined by ELISA (n=16, healthy controls; n=41, CHB). e) 
Correlation of serum arginase I with circulating gMDSC frequencies (n=24, CHB). Further 
cumulative analysis of the CHB cohort by: f) disease phase, g) serum ALT (IU/L). h) 
Tandem high-performance liquid chromatography mass spectrometry analysis of the L-
arginine concentration (μM) in sera (n=38, healthy controls; n=71, CHB). i) L-arginine 
concentration (μM) in sera from 7 CHB pre– and on antiviral therapy (for >1 year) and j) 
correlation between decline in liver inflammation on therapy (ALT, IU/L) and recovery of 
L-arginine levels. Error bars represent the mean ± SEM for the cohorts indicated; * p<0.05, 
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** p<0.01; *** p<0.001; b, d, h unpaired t test, i paired t test, e, g, j Pearson product-
moment correlation coefficient; c, f one way ANOVA (Tukey’s multiple comparisons test).
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Figure 4. Accumulation of arginase+ gMDSC in the liver
a) Representative FACS plots showing gMDSC (red) superimposed on the immature 
myeloid cell population from paired PBMC and intrahepatic leukocyte (IHL) samples, and 
the cumulative data depicting circulating compared to intrahepatic gMDSC frequencies 
(n=36, CHB). b) Cumulative data depicting expression (MFI) of arginase I in circulating and 
intrahepatic gMDSC (n=16, CHB). c) Surface CD63 expression (MFI) on peripheral and 
intrahepatic gMDSC (n=9, CHB). d) Representative and cumulative chemokine receptor 
expression on mMDSC and gMDSC of CCR2 and CXCR4. Representative and cumulative 
expression (%) on paired peripheral and intrahepatic gMDSC of e) CXCR3 (n=16, CHB) 
and f) CXCR1 (n=8, CHB). g) PBMC co-cultured with or without pHSC and analysed for 
gMDSC frequencies on day 6 (n=9, healthy controls, n=8, CHB). h) Representative double 
epitope immunostaining of liver sections from subjects with CHB for CD15 (brown, DAB) 
and CD66b (red, APAAP) at 100× magnification (top left); multispectral analysis (Nuance) 
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with CD15 (green, top right) and CD66b (red, bottom left) as pseudo-fluorescent images. 
Co-localization of CD15 and CD66b, represented in yellow; composite image (bottom 
right). i) Two representative examples of double epitope immunohistochemistry with CD3 
in red (APAAP) and CD66b in brown (DAB) at 400× magnification: arrows indicate CD3+ 
and CD66b+ cells in close association. Error bars represent the mean ± SEM for the cohorts 
indicated; * p<0.05; ** p<0.01; *** p<0.001; a-c, e-g paired t test; d unpaired t test.
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Figure 5. gMDSC suppress functional T cells in an arginase-1 dependent manner
gMDSC were enriched or depleted using sequential magnetic bead isolation (CD14−CD15+) 
from PBMC for direct co-culture with autologous PBMC. gMDSC–enriched (+ gMDSC), 
depleted (Δ gMDSC), or undepleted PBMC were cultured with 20 IU/ml recombinant IL-2 
for 5 days and stimulated to test T cell responses by intracellular cytokine production 
following peptide stimulation. a) Representative FACS plots showing the IFN-γ T cell 
response with or without stimulation with 1 μg/ml overlapping peptides spanning the core 
region of HBV genotype D, after gMDSC depletion or enrichment at day 0. b) Cumulative 
data depicting HBV-specific CD8+ and CD4+ T cell responses (subtraction of background in 
the absence of stimulation) in PBMC ± gMDSC (n=7, CHB). c) Representative FACS plots 
and d) cumulative data for IFN-γ+ CD8+ and CD4+ T cell responses to 0.5 μg/ml CEF-
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specific peptide stimulation (minus background as before) in PBMC ± gMDSC (n=18, 
CHB). Error bars represent the mean ± SEM for the cohorts indicated; * p<0.05, ** p<0.01; 
b, d paired t test. e) Fold change CD8+ IFN-γ− response to CEF peptide in PBMC or 
gMDSC enriched cultures in the presence or absence of arginase I specific inhibitor nor-
NOHA (n=3, CHB). Dotted line indicates response of CD8+ T cells without gMDSC 
enrichment or nor-NOHA. f) MFI of CD3-ζ on CD3ε+ T cells (dashed line) in relation to 
circulating gMDSC frequencies as a percentage of myeloid cells (solid line) at multiple time 
points throughout acute HBV infection (n=3, upper panel) and spontaneous hepatic flares of 
HBeAg− CHB (n=2, lower panel).
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Figure 6. Differential CD98 expression on T cells in CHB
a) Cumulative data depicting expression (MFI) of CD98 on CD3+ T cells (n=15, healthy 
controls; n=27, CHB). b) Representative histogram showing CD98 MFI on peripheral CD3+ 
(PBMC) and intrahepatic CD3+ (IHL) from a subject with CHB, and the cumulative paired 
data (n=11, CHB). c) Representative histogram showing CD98 MFI on global and HBV-
specific CD8+ T cells (identified by ex vivo staining with a panel of HLA-A2/HBV peptide 
dextramers) and the cumulative data (n=7, CHB). d) Representative example of 
identification of paired HBV– and CMV-specific CD8+ T cells using the relevant HLA-A2 
dextramers and comparison of their CD98 MFI ex vivo (n=7, CHB). e) Cumulative data 
showing CD98 MFI on CD3+ T cells post TCR stimulation (anti-CD3, anti-CD28) for 3 
days in cRPMI with a further 24 hr in the presence of 1.14 mM L-arginine (concentration in 
RPMI1640), 50 μM L-arginine, or in the absence of L-arginine (L-arginine free) (n=20, 
healthy controls). f) Co-expression of CD71 and CD98 on CD3+ T cells in the absence of L-
arginine for 24 hr post TCR stimulation (n=15, healthy controls). g) Uptake of radiolabelled 
amino acid (phenylalanine) in T cells post TCR stimulation, before culture varying 
concentrations of L-arginine for 24 hr. h) Radiolabelled phenylalanine uptake in the 
presence or absence of the system-L inhibitor BCH (10 mM) ± L-arginine deprivation (n=3, 
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healthy controls). Error bars represent the mean ± SEM for the cohorts indicated; * p<0.05; 
** p<0.01; *** p<0.001; a, e unpaired t test, b-d paired t test, f Pearson product-moment 
correlation coefficient.
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